Patents by Inventor Shon Li

Shon Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240124442
    Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.
    Type: Application
    Filed: February 3, 2022
    Publication date: April 18, 2024
    Applicant: AMGEN INC.
    Inventors: Albert AMEGADZIE, Diane Jennifer BEYLKIN, Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Kevin Lloyd GREENMAN, Todd J. KOHN, Kexue LI, Qingyian LIU, Ana Elena MINATTI, Primali Vasundera NAVARATNE, Liping H. PETTUS, Rene RAHIMOFF, Hui-Ling WANG, Nicholas Anthony WEIRES
  • Publication number: 20240101570
    Abstract: Described herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, such as cancer, metabolic and blood disorders. Compounds of Formula (I) have the following structure of Formula (I).
    Type: Application
    Filed: November 22, 2021
    Publication date: March 28, 2024
    Inventors: Albert AMEGADZIE, Diane Jennifer BEYLKIN, Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Sanne Ormholt Schroder GLAD, Todd J. KOHN, Brian Alan LANMAN, Kexue LI, Qingyian LIU, Patricia LOPEZ, Francesco MANONI, Primali Vasundera NAVARATNE, Liping H. PETTUS, Rene RAHIMOFF, Nuria A. TAMAYO, Mikkel VESTERGAARD, Hui-Ling WANG, Nicholas Anthony WEIRES
  • Publication number: 20210054367
    Abstract: The present invention relates to methods and compositions for modifying a target site in a DNA molecule. The present disclosure provides a DNA-targeting RNA duplex which comprises a crRNA molecule and a tracrRNA molecule and methods of using these molecules for modification of a target DNA. Modifications include targeted transgene insertion, targeted allelic replacement, and targeted mutagenesis.
    Type: Application
    Filed: April 30, 2019
    Publication date: February 25, 2021
    Applicant: SYNGENTA PARTICIPATIONS AG
    Inventors: Jiang Li, Jianping Xu, Shon Li, Lizhao Geng